

INVITROGEN CORP  
Form 8-K/A  
May 25, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K/A**

---

**AMENDMENT NO. 1 TO CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of The Securities Exchange Act Of 1934**

**Date of Report (Date of earliest event reported) February 6, 2004**

---

**INVITROGEN CORPORATION**

(Exact name of registrant as specified in charter)

---

**Delaware**  
(State or other jurisdiction)

of incorporation)

**1600 Faraday Avenue, Carlsbad, CA**  
(Address of principal executive offices)

**0-25317**  
(Commission File Number)

**33-0373077**  
(IRS Employer

Identification No.)

**92008**  
(Zip Code)

**Registrant's telephone number, including area code (760) 603-7200**

**Not applicable**

**(Former name or former address, if changed since last report)**

---

This Amendment No. 1 to the Current Report on Form 8-K/A is filed for the purpose of filing the pro forma combined results of operations of Invitrogen Corporation and BioReliance Corporation for the three months ended March 31, 2004.

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

- (a) Financial statements of business acquired.

The audited financial statements required by this Item 7 for BioReliance, as of and for the year ended December 31, 2003, were filed as Exhibit 99.1 to the Form 8-K/A filed on April 21, 2004, and are incorporated herein by reference.

- (b) Pro forma financial information.

The pro forma financial information required by this Item 7 for the combined balance sheet of Invitrogen and BioReliance, as of December 31, 2003, and for the combined results of operations of Invitrogen, BioReliance, Molecular Probes, Inc., and the assets acquired and liabilities assumed from PanVera LLC for the year ended December 31, 2003, was filed as Exhibit 99.2 to the Form 8-K/A filed on April 21, 2004 and is incorporated herein by reference. The pro forma financial information required by this Item 7 for the combined statement of income of Invitrogen and BioReliance for the three months ended March 31, 2004, is included herein as Exhibit 99.3 and incorporated by reference.

- (c) Exhibits.

<u>Exhibit</u>	<u>Description</u>
99.3	Invitrogen Corporation and BioReliance Corporation Unaudited Pro Forma Combined Statement of Income for the three months ended March 31, 2004, and related Notes to Combined Financial Statement.

